(110 days)
The NEON EEG is intended to be applied directly to the patient's scalp to enable recordings of electrophysiological signals (such as EEG) on infants from birth. The NEON EEG is indicated for single use only and should be replaced after 12 hours of use. The NEON EEG is not indicated for use with electro stimulation equipment.
The NEON EEG consists of an array of pre-gelled electrodes that are sized to fit an infant's scalp. The electrodes are screen-printed in Ag/AgCl ink on a flexible polyester substrate and are pre-gelled with industry-standard electrode paste. The electrode array substrate has a thin layer of inert foam. The electrode array connects to a monitoring machine by an interface cable with medically-recognized safety end fittings ("touch proof" or "D type"). The safety connector is connected to the electrically and patient-isolated pre-amplifier input of a neuro-diagnostic or neuro-monitoring equipment. The NEON electrode array is sized to fit new-born infants and has a reduced lead set of 5 pairs of electrodes, plus a Ground and Reference. The positioning of the electrodes is based upon the principles of the 10-20 placement system, with individual electrodes labeled with their 10-20 nomenclature. The shape of the array is designed to allow access to the scalp, co-exist with other monitoring requirements, and allow free circulation of air. An industry-standard EEG electrolyte gel is supplied to allow optional application on individual electrodes sites.
It appears the provided document is a 510(k) summary for a medical device called "NEON EEG," which is a cutaneous electrode intended for recording electrophysiological signals (like EEG) on infants.
However, the document does not contain a study or data proving the device meets specific acceptance criteria in the way you've outlined. Instead, it focuses on demonstrating substantial equivalence to predicate devices based on:
- Intended Use: Similar purpose.
- Technological Characteristics: Similar materials (Ag/AgCl ink, pre-gelled electrodes, polyester substrate, foam backing), similar connection to monitoring equipment, adherence to 10-20 placement system principles.
- Principles of Operation: Implied to be the same as other EEG electrodes.
- Performance Standards: Compliance with IEC60601-1-2:2007 (EMC), AAMI EC12: 2005 (Disposable ECG electrodes), and IEEE 2010:2012 (Neurofeedback Systems). The document states, "In all instances, the NEON EEG functioned as intended." This is a general statement of compliance, not a detailed study with specific performance metrics and acceptance thresholds.
The document emphasizes that differences are minor (e.g., sizing for infants, number of electrodes to fit a smaller scalp) and "raise no new issues of safety or effectiveness." It concludes that "Performance data demonstrate that the NEON EEG is safe and effective in use. Thus, the NEON EEG is substantially equivalent." without detailing what this performance data entails.
Therefore, I cannot fill out your requested table and study information as the provided text does not contain the specific data points you're looking for (e.g., quantitative acceptance criteria, reported performance metrics, sample sizes for test/training sets, ground truth establishment, expert qualifications, MRMC studies, standalone performance).
To summarize why I cannot provide the requested information:
- No explicit acceptance criteria table: The document references compliance with performance standards (IEC, AAMI, IEEE) but doesn't define specific quantitative "acceptance criteria" and "reported device performance" in a structured table for the device's primary function (EEG signal quality, impedance, etc.).
- No detailed study data: The 510(k) summary is designed to establish substantial equivalence, not to present a detailed clinical or performance study with quantified results, sample sizes, or ground truth methodologies.
- Focus on Substantial Equivalence: The approval is based on equivalence to predicate devices, implying that if the predicate devices are safe and effective, and the new device is sufficiently similar, it also is. This approach often doesn't require new, extensive clinical performance studies to the same degree as a PMA.
- Device Type: This is a cutaneous electrode, which is a fairly mature and well-understood technology. The "safety and effectiveness" cited likely refers to standard electrical safety, biocompatibility, and basic signal integrity, rather than complex diagnostic accuracy.
If you have a document that details a specific performance study with quantitative results, I would be able to answer your questions.
{0}------------------------------------------------
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
September 29, 2015
Incereb Ltd Paul Phillips QA/RA Manager Centre Of Applied Science For Health, Institute Of Technology Tallaght Dublin. IE DUBLIN24
Re: K151576
Trade/Device Name: Neon EEG Regulation Number: 21 CFR 882.1320 Regulation Name: Cutaneous Electrode Regulatory Class: Class II Product Code: GXY Dated: June 4, 2015 Received: June 17, 2015
Dear Paul Phillips:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in
{1}------------------------------------------------
the quality systems (OS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
Carlos L. Pena -S 同公
Carlos L. Peña, PhD, MS Director Division of Neurological and Physical Medicine Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
{2}------------------------------------------------
Indications for Use
510(k) Number (if known) K151576
Device Name NEON EEG
Indications for Use (Describe)
The NEON EEG is intended to be applied directly to the patient's scalp to enable recordings of electrophysiological signals (such as EEG) on infants from birth. The NEON EEG is indicated for single use only and should be replaced after 12 hours of use.
The NEON EEG is not indicated for use with electro stimulation equipment.
Type of Use (Select one or both, as applicable)
| ☑ Prescription Use (Part 21 CFR 801 Subpart D) |
|---|
| □ Over-The-Counter Use (21 CFR 801 Subpart C) |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
{3}------------------------------------------------
V. 510(K) SUMMARY
510(k) SUMMARY
Incereb Ltd's NEON EEG
Submitter's Name, Address, Telephone Number, Contact Person and Date Prepared
Incereb Ltd Centre of Applied Science for Health Institute of Technology, Tallaght Dublin 24 IRELAND
Phone: +353 1 685 2245 EMail: pphillips@incereb.com
Contact Person: Paul Phillips
Date Prepared: 4th June 2015
Name of Device
NEON EEG
Common or Usual Name
Cutaneous Electrode
Classification Name/Product Code/CFR Reference
Class II, Cutaneous Electrode, Product code: GXY, 21 CFR 882.1320,
Predicate Devices
Primary Predicate: Aspect Medical Systems' BIS Bilateral Sensor (K062692) Secondary Predicate: Aspect Medical Systems' BIS Pediatric Sensor (K041670)
Intended Use / Indications for Use
The NEON EEG is intended to be applied directly to the patient's scalp to enable recordings of electrophysiological signals (such as EEG) on infants from birth.
The NEON EEG is indicated for single use only and should be replaced after 12 hours of use.
The NEON EEG is not indicated for use with electro stimulation equipment
{4}------------------------------------------------
Technological Characteristics
The NEON EEG consists of an array of pre-gelled electrodes that are sized to fit an infant's scalp. The electrodes utilize materials that are common in sensing technology: The electrodes are screen-printed in Ag/AgCl ink on a flexible polyester substrate. The electrodes are pre-gelled with industry-standard electrode paste that provides both the intimate electrical connection and the adhesion to the scalp. The electrode array substrate has a thin layer of inert foam to provide comfort to the patient whilst the device is being worn.
The electrode array connects to a monitoring machine by an interface cable that has medically-recognized safety end fittings ("touch proof" or "D type") that cannot be inserted into an AC outlet. The safety connector is connected to the electrically and patient-isolated pre-amplifier input of a neuro-diagnostic or neuro-monitoring equipment. All of the electrical safety features are provided by the neuro-diagnostic or neuro-monitoring equipment.
The NEON electrode array is sized to fit new-born infants and so has a reduced lead set of 5 pairs of electrodes, with each pair having an electrode on opposite sides of the head, plus a Ground and Reference. The positioning of the electrodes in the array is based upon the principles of the 10-20 placement system, with the individual electrodes labeled with their 10-20 nomenclature. The shape of the array is designed to allow as much access to the scalp as possible, so that the NEON EEG can co-exist with other monitoring requirements and to allow the free circulation of air to the infant's head and thus not contribute to cranial overheating.
An industry-standard EEG electrolyte qel is supplied in the device package to allow optional application on individual electrodes sites, should it be required to reduce the electrode impedance.
Performance Standards
The NEON EEG has been tested to the relevant parts of the following recognized performance standards:
- IEC60601-1-2:2007 Medical electrical equipment Part 1-2: General ● requirements for basic safety and essential performance - Collateral standard: Electromagnetic compatibility - Requirements and tests
- AAMI EC12: 2005 - Disposable ECG electrodes
- . IEEE 2010:2012 - IEEE Recommended Practice for Neurofeedback Systems
In all instances, the NEON EEG functioned as intended.
{5}------------------------------------------------
Substantial Equivalence
The NEON EEG is as safe and effective as the Aspect Medical Systems' BIS Bilateral Sensor (K062692). The NEON EEG has the same intended use, main technological characteristics, and principles of operation as its predicate device. The indications for use of the primary predicate device do not indicate that it is only for adult patients, though the device sizing implies it as it would be too large for a new-born. The secondary predicate (K041670) is of the same technology as both the primary predicate and the NEON, it has just 4 electrodes in its array, to allow it to be applied to a pediatric scalp. The secondary predicate's indications for use do specifically cite pediatric use.
The NEON and the two predicate devices all share the same technology, they just differ in minor technical implementations and in the number of electrodes in their electrode array, which is a feature to enable the devices to suit the size of the scalp of the patients in their intended use/indications for use. These minor differences between the NEON EEG and its predicate devices raise no new issues of safety or effectiveness. Performance data demonstrate that the NEON EEG is safe and effective in use. Thus, the NEON EEG is substantially equivalent.
§ 882.1320 Cutaneous electrode.
(a)
Identification. A cutaneous electrode is an electrode that is applied directly to a patient's skin either to record physiological signals (e.g., the electroencephalogram) or to apply electrical stimulation.(b)
Classification. Class II (performance standards).